Did you know?

The Merck spinoff Organon will likely do quite well. OGN stock is likely to be worth $52.77, or 48% above the when-issued price right now.Second annual report highlights company’s advancements with a focus on innovation and access to ensure a healthier, more sustainable future for women worldwide. Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report . The …Investor Relations – Form 10 FAQ . As of 3/17/2021 . On March 17. th, Merck announced the filing of Form 10 Registration Statement in connection with the planned spinoff of Organon & Co. (Organon). Merck also announced the date of its virtual investor day, which will take place on May 3rd.Media Contacts: Karissa Peer Investor Contacts: Jennifer Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Edward Barger (267) 614-4669 Organon reports results for the fourth quarter and full year ended December 31, 2021 Nexplanon ®(etonogestrel implant), fertility, biosimilars grew double digits for full yearFeb 16, 2023 · I would like now to turn the call over to Jennifer Halchak, Vice President, Investor Relations. Please begin your conference. ..... Jennifer Halchak Vice President -Investor Relations, Organon & Co. Thank you, Dennis. Good morning, everyone. Thank you for joining Organon's fourth quarter and full -year 2022 earnings call. Executive Leadership Team. Our Executive Team manages the strategic direction and operations of our company. With their broad and varied experiences, they guide who we are and what we stand for. Second quarter 2022 revenues of $1,585 million Second quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25 Both reported and non-GAAP adjusted diluted earnings per share include a negative impact of $0.30 for acquired in-process research and development (IPRD) and milestones Adjusted EBITDA ...04/20/2023. Compass Minerals Announces Conference Call to Discuss Fiscal 2023 Second-Quarter Results. Download. 03/06/2023. Compass Minerals Announces Participation in Loop Capital Markets 2023 Investor Conference. Download. 02/22/2023. Compass Minerals Announces Participation in BMO Global Metals, Mining & Critical …Organon Reports Results for the Third Quarter Ended September 30, 2021. Third quarter 2021 revenue of $1,600 million. Net income from continuing operations of $323 million, or $1.27 per diluted ...This presenta tion will also be available following this call on the Events and Presentations section of our Organon Investor Relations website at www.organon.com. Before we begin I would like to caution listeners that certain information discussed by management during this conference call will include forward -looking statements. Actual Just 4% of all healthcare research and development is focused on women’s health, and women are still underrepresented in nearly all clinical trials. i. Organon’s portfolio and innovation pipeline are focused on these key …The separation of Organon & Co. should enable roughly $1.5 billion in pre-tax operating efficiencies, ratable over three years, and Merck is targeting operating margins of greater than 40% in 2024, higher than what would have achieved as a combined company. 6. When will the rest of the management team and board be announced?Collaboration expands and underscores commitment to biosimilars portfolio and focus on women’s health with biosimilar candidates for osteoporosis and breast cancer Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai Henlius Biotech, Inc. (2696.HK), whereby Organon will ...See the company profile for Organon & Co. (OGN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...Organon 330 688 737 694 Gross Debt (2) 9,348 9,298 9,134 9,094 Net Debt (2) 9,018 8,610 8,397 8,400 (1) Organon’s starting cash balance at spin included $400 million from Merck & Co., Inc., Rahway, NJ, USA which was used for the purchase of inventory upon exit of certain Interim Operating Model arrangements.2023-04-20 13:30. Organon To Report First Quarter and Host Conference Call on May 4, 2023. Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call ...To look up the employer identification number of a publicly traded company, visit the investor relations website of the company, or use the EDGAR filings database maintained by the U.S. Securities and Exchange Commission.Standalone company positioned to deliver low to mid-single digit revenue growth off 2021 base Future growth opportunities include Women’s Health and Biosimilars businesses; Established Brands portfolio expected to provide significant cash flow to invest in new opportunities, with modest future LOE risk after 2021 Organon will have a diverse …© 2023 Organon group of companies. All rightsExecutive Leadership Team. Our Executive Team m First quarter 2023 revenue of $1,538 million First quarter 2023 diluted earnings per share of $0.69 and non-GAAP Adjusted diluted earnings per share of $1.08 Both reported and non-GAAP Adjusted diluted earnings per share include a negative impact of $0.03 per share for acquired in-process research and development (IPR&D) Adjusted EBITDA of $518 million, inclusive of $8 million of acquired IPR ... Organon and CAF, Development Bank of Latin America, Launch First-of- Alex Arzeno. (203) 550-3972. Source: Organon & Co. Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website ... Investor relations Our science-led strategy is key to delivering long

Contact Investor Relations. 551-430-6900. [email protected]. View Organon’s latest filings with the United States Securities and Exchange Commission.Jun 30, 2022 · Second quarter 2022 revenues of $1,585 million Second quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25 Both reported and non-GAAP adjusted diluted earnings per share include a negative impact of $0.30 for acquired in-process research and development (IPRD) and milestones Adjusted EBITDA ... Organon will host a conference call at 8:30 a.m. Eastern Time today to discuss its second quarter 2022 financial results. To listen to the event and view the …Alex Arzeno. (203) 550-3972. Source: Organon & Co. Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon …

Organon & Co (NYSE:NYSE:OGN) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - CEO & DirectorMatthew Walsh - EVP...An estimated 21 million American women experience BV Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced they have entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). XACIATO is an FDA-approved medication for the ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Media Contacts: Karissa Peer Investor Contacts: Jennifer Halc. Possible cause: … Advertisement U.S. markets close in 16 minutes S&P Futures 4,414.25 +4.50 (.